BMO Capital Markets reiterated their outperform rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a report published on Friday. The brokerage currently has a $134.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $99.00.

A number of other brokerages have also weighed in on ALNY. Cowen and Company restated a buy rating and issued a $100.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, July 11th. Jefferies Group LLC set a $102.00 price objective on Alnylam Pharmaceuticals and gave the company a buy rating in a report on Friday, August 25th. Barclays PLC raised their price objective on Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the company an equal weight rating in a report on Thursday, August 10th. Credit Suisse Group raised their price objective on Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the company an outperform rating in a report on Tuesday, June 27th. Finally, Leerink Swann restated a market perform rating and issued a $72.00 price objective (down previously from $83.00) on shares of Alnylam Pharmaceuticals in a report on Friday, September 8th. They noted that the move was a valuation call. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the stock. Alnylam Pharmaceuticals has a consensus rating of Hold and an average target price of $93.11.

Alnylam Pharmaceuticals (ALNY) traded up 0.78% during midday trading on Friday, reaching $113.80. 2,339,648 shares of the company were exchanged. The stock’s market capitalization is $10.44 billion. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $118.40. The firm’s 50 day moving average price is $81.14 and its 200-day moving average price is $69.12. Alnylam Pharmaceuticals also saw some unusual options trading on Wednesday. Investors acquired 30,530 call options on the company. This represents an increase of approximately 937% compared to the typical daily volume of 2,944 call options.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.12). The firm had revenue of $15.93 million during the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The company’s revenue for the quarter was up 82.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.05) EPS. Equities analysts forecast that Alnylam Pharmaceuticals will post ($5.19) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals’ (ALNY) “Outperform” Rating Reaffirmed at BMO Capital Markets” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/alnylam-pharmaceuticals-alny-outperform-rating-reaffirmed-at-bmo-capital-markets/1583102.html.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the completion of the transaction, the president now directly owns 165,399 shares of the company’s stock, valued at approximately $16,539,900. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.30% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Pacer Advisors Inc. grew its position in shares of Alnylam Pharmaceuticals by 22.0% during the second quarter. Pacer Advisors Inc. now owns 11,610 shares of the biopharmaceutical company’s stock worth $926,000 after buying an additional 2,093 shares in the last quarter. TLP Group LLC acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth about $380,000. Wellington Management Group LLP grew its position in shares of Alnylam Pharmaceuticals by 0.3% during the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock worth $617,111,000 after buying an additional 31,208 shares in the last quarter. Hemenway Trust Co LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $235,000. Finally, BlackRock Inc. grew its position in shares of Alnylam Pharmaceuticals by 34,755.2% during the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock worth $243,242,000 after buying an additional 4,732,617 shares in the last quarter. 94.25% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.